journal
Journals Therapeutic Advances in Medica...

Therapeutic Advances in Medical Oncology

https://read.qxmd.com/read/38745586/clinical-activity-of-pembrolizumab-in-refractory-mdm2-amplified-advanced-intimal-sarcomas
#1
Mauricio Fernando Ribeiro, Elizabeth G Demicco, Albiruni Ryan Abdul Razak
Intimal sarcoma (InS) is an ultra-rare and aggressive subtype of soft tissue sarcoma (STS). It usually arises in large mediastinal arteries and the heart. In the advanced setting, sequential cytotoxic chemotherapy is often used, mainly based on retrospective studies and case series but with modest benefit. The use of immune checkpoint inhibitors is a promising strategy for some STS, but identifying biomarkers of response remains challenging due to disease rarity and heterogeneity. A reactive and pro-inflammatory tumor microenvironment (TME) is believed to be associated with better outcomes for patients receiving anti-PD-1-based regimens, generating the rationale to explore this strategy in malignancies with this characteristic, such as InS...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38736555/assessment-of-efficacy-and-safety-of-met-tyrosine-kinase-inhibitors-in-non-small-cell-lung-cancer-patients-with-met-alterations
#2
JOURNAL ARTICLE
Yanhua Wang, Manyi Xu, Ke Wang, Yue Hao, Chunwei Xu, Zhengbo Song
BACKGROUND: While targeted therapy has become the standard treatment for certain non-small-cell lung cancer (NSCLC) patients with gene mutation positivity, there remains a lack of enough reports of the efficacy of mesenchymal-epithelial transition (MET) alterations in the real world. OBJECTIVES: We aimed to explore the efficacy and toxicity of targeted therapy in NSCLC patients with different types of MET alterations and hope to provide more clinical medication guidance...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38736554/real-world-analysis-of-afatinib-as-a-first-line-treatment-for-patients-with-advanced-stage-non-small-cell-lung-cancer-with-uncommon-egfr-mutations-a-multicenter-study-in-vietnam
#3
JOURNAL ARTICLE
Van Luan Pham, Tuan Anh Le, Cam Phuong Pham, Thi Thai Hoa Nguyen, Anh Tu Do, Tuan Khoi Nguyen, Minh Hai Nguyen, Thi Anh Thu Hoang, Dinh Thy Hao Vuong, Dac Nhan Tam Nguyen, Van Khiem Dang, Thi Oanh Nguyen, Thi Huyen Trang Vo, Hung Kien Do, Ha Thanh Vu, Thi Thuy Hang Nguyen, Van Thai Pham, Le Huy Trinh, Khac Dung Nguyen, Hoang Gia Nguyen, Cong Minh Truong, Tran Minh Chau Pham, Thi Bich Phuong Nguyen
BACKGROUND: Afatinib is indicated for advanced-stage non-small-cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) and uncommon mutations. However, real-world studies on this topic are limited. This study aimed to evaluate afatinib as first-line therapy for locally advanced and metastatic NSCLC with uncommon EGFR mutations. PATIENTS AND METHODS: A retrospective study included 92 patients with advanced NSCLC with uncommon and compound EGFR mutations, treated with afatinib as first-line therapy...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38736553/efficiency-of-bladder-sparing-strategies-for-bladder-cancer-an-umbrella-review
#4
REVIEW
Deng-Xiong Li, Qing-Xin Yu, Rui-Cheng Wu, Jie Wang, De-Chao Feng, Shi Deng
Bladder preservation (BP) has emerged as a clinical alternative to radical cystectomy (RC) for alleviating the substantial physical and psychological burden imposed on localized bladder cancer patients. Nevertheless, disparities persist in the comparative evaluations of BP and RC. We aimed to address the disparities between BP and RC. An umbrella review and meta-analysis were conducted to explore these disparities. We extracted data from meta-analyses and randomized controlled trials (RCTs) selected after searching PubMed, Embase, Web of Science, and the Cochrane Database of Systematic Reviews...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38736552/assessment-of-the-impact-of-residual-tumors-at-different-sites-post-neoadjuvant-chemotherapy-on-prognosis-in-breast-cancer-patients-and-development-of-a-disease-free-survival-prediction-model
#5
JOURNAL ARTICLE
Hanzhao Yang, Yuxia Ruan, Yadong Sun, Peili Wang, Jianghua Qiao, Chengzheng Wang, Zhenzhen Liu
BACKGROUND: Residual disease after neoadjuvant chemotherapy (NAC) in breast cancer patients predicts worse outcomes than pathological complete response. Differing prognostic impacts based on the anatomical site of residual tumors are not well studied. OBJECTIVES: The study aims to assess disease-free survival (DFS) in breast cancer patients with different residual tumor sites following NAC and to develop a nomogram for predicting 1- to 3-year DFS in these patients...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38716480/prognostic-value-of-pathological-nodal-burden-after-neoadjuvant-chemotherapy-in-initially-cn0-1-breast-cancer-patients-a-dual-center-10-year-survival-analysis
#6
JOURNAL ARTICLE
Amina Maimaitiaili, Zhimin Fan, Jingyi Zhang, Yidi Wang, Bohui Shi, Jie Zheng, Gefei Li, Yuting Zhao, Shengyu Pu, Jianjun He, Fengjiang Qu, Huimin Zhang
BACKGROUND: There is an interest in performing de-escalating axillary surgery after neoadjuvant chemotherapy (NAC). However, the significance of residual axillary node disease after NAC has not been well studied. OBJECTIVES: To investigate the pathological residual axillary lymph node tumor burden (ypN) of patients with initial clinical nodal stage cN0-1 breast cancer after NAC and determine its prognostic value. DESIGN: Initial cN0-1 breast cancer patients who received NAC followed by axillary surgery at the First Hospital of Jilin University and the First Affiliated Hospital of Xi'an Jiaotong University between January 2011 and December 2019 were included...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38716479/role-of-immunotherapy-in-pulmonary-sarcomatoid-carcinoma-review-of-current-approaches-and-related-biomarkers
#7
REVIEW
Kaibo Ding, Zhongsheng Peng, Yanjun Xu
Pulmonary sarcomatoid carcinoma (PSC), a rare subtype of non-small cell lung cancer, is highly malignant and has a poor prognosis. Treatments for PSC are presently limited. Traditional treatments provide fewer benefits to PSC patients and are associated with early recurrence and metastasis. Surgical intervention is the preferred option for early-stage PSC patients, whereas chemotherapy, radiotherapy, immunotherapy, and other targeted therapies are recommended for advanced PSC patients. Targeted therapy is only effective in a small number of PSC patients...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38716478/the-concomitant-use-of-the-renin-angiotensin-system-inhibitors-and-survival-outcomes-of-patients-with-pancreatic-adenocarcinoma-an-analysis-from-a-tertiary-center
#8
JOURNAL ARTICLE
Kuan-Yu Tseng, Chiann-Yi Hsu, Yu-Hsuan Shih, Hsin-Chen Lin, You-Cheng Li, Chieh-Lin Jerry Teng, Cheng-Wei Chou
BACKGROUND: The limited efficacy of chemotherapy in improving survival in pancreatic ductal adenocarcinoma (PDAC) necessitates the exploration of novel strategies to overcome treatment resistance. OBJECTIVES: This study aimed to investigate the impact of combining renin-angiotensin system (RAS) blockers with chemotherapy on survival outcomes in patients with PDAC. DESIGN: Patients with PDAC were enrolled in the retrospective study. METHODS: We analyzed patients with PDAC ( n  = 384) at our institution between 2014 and 2021...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38686016/tropion-breast03-a-randomized-phase-iii-global-trial-of-datopotamab-deruxtecan-%C3%A2-durvalumab-in-patients-with-triple-negative-breast-cancer-and-residual-invasive-disease-at-surgical-resection-after-neoadjuvant-therapy
#9
JOURNAL ARTICLE
Aditya Bardia, Lajos Pusztai, Kathy Albain, Eva Maria Ciruelos, Seock-Ah Im, Dawn Hershman, Kevin Kalinsky, Claudine Isaacs, Delphine Loirat, Laura Testa, Eriko Tokunaga, Jiong Wu, Hannah Dry, William Barlow, Robert Kozarski, Micah Maxwell, Nadia Harbeck, Priyanka Sharma
BACKGROUND: Despite advances in the treatment of early triple-negative breast cancer (TNBC), patients with residual invasive disease after neoadjuvant therapy have a high risk of disease recurrence and worse survival outcomes than those who have pathological complete response (pCR). Improving outcomes in early TNBC remains an unmet need requiring new adjuvant treatment approaches. Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate comprising a humanized anti-trophoblast cell-surface antigen 2 immunoglobulin G1 (IgG1) monoclonal antibody attached via a plasma-stable, cleavable linker to a potent topoisomerase I inhibitor payload, with activity observed in advanced TNBC...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38680292/pembrolizumab-induced-nephrotoxicity-in-a-patient-with-breast-cancer
#10
Samer Alkassis, Kasey Fitzsimmons, Sara Hurvitz
The introduction of immunotherapy has revolutionized the treatment and improved outcomes of multiple types of cancer. Although breast cancer is a less immune-responsive tumor type, the incorporation of pembrolizumab into chemotherapy regimens in the neoadjuvant and first-line metastatic setting for the triple-negative disease has improved outcomes. However, the use of this type of treatment is associated with a spectrum of adverse events. Although rarely affected, kidneys can be a target for immunotherapy, leading to irreversible injury if not recognized and addressed early...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38680291/dysregulation-of-base-excision-repair-factors-associated-with-low-tumor-immunogenicity-in-head-and-neck-cancer-implication-for-immunotherapy
#11
JOURNAL ARTICLE
Zackary Shpilman, Dawit Kidane
BACKGROUND: Head and neck squamous carcinoma (HNSCC) is caused by different exogenous risk factors including smoking cigarettes, alcohol consumption, and HPV infection. Base excision repair (BER) is the frontline to repair oxidative DNA damage, which is initiated by the DNA N -glycosylase proteins (OGG1) and other BER factors including DNA polymerase β (POLB). OBJECTIVE: Explore whether BER genes' ( OGG1 , POLB ) overexpression in HNSCC alters genomic integrity, immunogenicity, and its role in prognostic value...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38680290/treatment-with-nanosomal-paclitaxel-lipid-suspension-versus-conventional-paclitaxel-in-metastatic-breast-cancer-patients-a-multicenter-randomized-comparative-phase-ii-iii-clinical-study
#12
JOURNAL ARTICLE
Chiradoni Thungappa Satheesh, Rakesh Taran, Jitendra Kumar Singh, Shanti Prakash Shrivastav, Nikunj K Vithalani, Kalyan Kusum Mukherjee, Rajnish Vasant Nagarkar, Tanveer Maksud, Ajay Omprakash Mehta, Krishnan Srinivasan, Mummaneni Vikranth, Satish Ramkrishna Sonawane, Ateeq Ahmad, Saifuddin Sheikh, Shoukath M Ali, Ronak Patel, Mahesh Paithankar, Lav Patel, Anil Rajani, Deepak Bunger, Alok Chaturvedi, Imran Ahmad
BACKGROUND: A novel nanosomal paclitaxel lipid suspension (NPLS), free from Cremophor EL (CrEL) and ethanol, was developed to address the solvent-related toxicities associated with conventional paclitaxel formulation. OBJECTIVE: To evaluate the efficacy and safety of NPLS versus CrEL-based paclitaxel (conventional paclitaxel) in patients with metastatic breast cancer (MBC). DESIGN: A prospective, open-label, randomized, multiple-dose, parallel, phase II/III study...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38665845/improving-olaparib-exposure-to-optimize-adverse-effects-management
#13
JOURNAL ARTICLE
Marylise Sterlé, Alicja Puszkiel, Chloé Burlot, Eva Pereira, Audrey Bellesoeur, Sixtine De Percin, Guillaume Beinse, Jean-David Fumet, Laure Favier, Julie Niogret, Benoit Blanchet, Bernard Royer, Leïla Bengrine-Lefevre, Antonin Schmitt
BACKGROUND: Olaparib is an inhibitor of the human poly-(ADP-ribose)-polymerase enzymes (PARP1/2) needed to repair single-strand DNA breaks. It is used in breast, ovarian, prostate and pancreatic cancer. OBJECTIVES: This work aimed to describe the pharmacokinetics/pharmacodynamics (PK/PD) relationship between olaparib plasma concentrations and common adverse effects (i.e. anaemia and hypercreatininaemia), in a real-life setting, to propose a target concentration for therapeutic drug monitoring...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38655393/assessing-the-effectiveness-of-targeted-agents-in-adjuvant-therapy-for-patients-with-metastatic-colorectal-cancer-undergoing-surgical-resection-a-retrospective-cohort-study
#14
JOURNAL ARTICLE
Yi-Chia Su, Chih-Chien Wu, Yu-Hsun Chen, Chien-Chou Su, Yu-Ching Chang, Meng-Che Hsieh, Yea-Huei Kao Yang
BACKGROUND: Primary tumor resection and metastasectomy may be beneficial for many patients with metastatic colorectal cancer (mCRC). OBJECTIVE: To assess the differences in postoperative survival outcomes between adjuvant therapy with chemotherapy alone and chemotherapy plus targeted agents (TAs). DESIGN: Retrospective cohort study. METHODS: Patients with mCRC who underwent surgical resection for primary colorectal tumor and distant metastases and received adjuvant therapy from 1 January 2010 to 31 December 2017 were enrolled in the Taiwan Cancer Registry...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38645422/navigating-uncharted-territory-a-case-report-and-literature-review-on-the-remarkable-response-to-personalized-crizotinib-containing-combinational-therapy-in-a-pazopanib-refractory-patient-with-novel-alterations
#15
Esranur Aydın, Ünal Metin Tokat, Eylül Özgü, Ashkan Adibi, Onur Tutar, Razelle Kurzrock, Mutlu Demiray
This paper presents a patient with a novel Ig-like-III domain fibroblast growth factor receptor (FGFR2) alteration (W290_P307>C) along with CDKN2A/B alterations and a cadherin 1 (CDH1) alteration. Initial responsiveness to pazopanib monotherapy was encouraging, yet progression occurred after 7.5 months. Following progression, the molecular tumor board recommended a combination therapy approach comprising pazopanib, crizotinib, and palbociclib to target all of the changed pathways at the same time...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38638285/personalized-treatment-with-parp-inhibitors-in-advanced-urothelial-carcinoma-a-case-report-and-literature-review
#16
Noura Abbas, Laudy Chehade, Ali Shamseddine
Bladder cancer (BC) poses a significant health challenge, particularly in metastatic cases, where the prognosis is unfavorable and therapeutic options are limited. Poly ADP-ribose polymerase (PARP) inhibitors have gained approval for use in various cancer types, but their application in BC remains controversial, despite the notable prevalence of DNA damage response alterations in advanced or metastatic urothelial carcinomas. In this report, we describe a 66-year-old heavy-smoking female diagnosed with muscle-invasive BC...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38628554/real-world-experience-supporting-the-role-of-oncologic-resection-and-adjuvant-chemotherapy-in-biliary-tract-cancers
#17
JOURNAL ARTICLE
Melina Boutin, Tharani Krishnan, Maria Safro, Jenny Yang, Helia Jafari, Janine M Davies, Sharlene Gill
BACKGROUND: Complete resection followed by adjuvant chemotherapy is the gold standard for patients with localized cholangiocarcinoma (CC) or gallbladder cancer (GBC). However, this is not always feasible, and recurrence rates remain high. OBJECTIVES: To understand the real-world proportions and reason for treatment failure in resected biliary tract cancers. DESIGN AND METHODS: We performed a retrospective population-based review of patients with GBC or CC [intrahepatic (IHCC) or extrahepatic (EHCC)] resected between 2005 and 2019 using the BC Cancer provincial database...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38617024/real-world-study-of-hepatic-artery-infusion-chemotherapy-combined-with-anti-pd-1-immunotherapy-for-hepatocellular-carcinoma-patients-with-portal-vein-tumor-thrombus
#18
JOURNAL ARTICLE
Jinghuan Li, Bing Quan, Wenfeng Liu, Menglong Zhao, Fan Yao, Rongxin Chen, Zhenggang Ren, Xin Yin
BACKGROUND: Patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) present a poor prognosis. Current systemic therapies offer limited benefits. Hepatic artery infusion chemotherapy (HAIC) is a local regional treatment for advanced HCC, particularly in selected patients such as patients with PVTT or high intrahepatic tumor burden. OBJECTIVES: The purpose of this study is to retrospectively evaluate the efficacy and safety of HAIC combined with anti-PD-1 immunotherapy for HCC patients with PVTT, and explore factors related to survival prognosis, providing clues for treatment decisions for HCC patients...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38617023/clinicopathologic-characteristics-of-hpv-associated-head-and-neck-squamous-cell-carcinoma-in-southern-china-long-term-retrospective-study-of-400-cases
#19
JOURNAL ARTICLE
Mingyuan Du, Qiaohong Lin, Shida Yan, Xianlu Gao, Chulin Yang, Zhaoyang Li, Wei Liao, Ankui Yang, Shuwei Chen
BACKGROUND: Human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) is an evolving and growing disease, especially in developing countries. However, the clinical characteristics of HPV-associated HNSCC in regard to HPV infection rates, patient features, and prognosis are under-reported in the Asian population. METHODS: In this study, we retrospectively enrolled a 400-case cohort of HNSCC with p16 immunochemistry and analyzed with long-term follow-up...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38606165/unraveling-the-tumor-immune-microenvironment-of-lung-adenocarcinoma-using-single-cell-rna-sequencing
#20
REVIEW
Lele Song, Yuan Gong, Erpeng Wang, Jianchun Huang, Yuemin Li
Tumor immune microenvironment (TIME) and its indications for lung cancer patient prognosis and therapeutic response have become new hotspots in cancer research in recent years. Tumor cells, immune cells, various regulatory factors, and their interactions in the TIME have been suggested to commonly influence lung cancer development and therapeutic outcome. The heterogeneity of TIME is composed of dynamic immune-related components, including various cancer cells, immune cells, cytokine/chemokine environments, cytotoxic activity, or immunosuppressive factors...
2024: Therapeutic Advances in Medical Oncology
journal
journal
42443
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.